AstraZeneca vs. Natco: Consent Judgment Resolves Acalabrutinib Generic Patent Battle
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | AstraZeneca Inc. et al. v. Natco Pharma Ltd. et al. |
| Case Number | 1:22-cv-00155 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Feb 2022 – Apr 2024 2 years 2 months |
| Outcome | Plaintiff Win — Consent Judgment & Permanent Injunction |
| Patents at Issue | |
| Accused Products | Generic Acalabrutinib 100 mg Oral Capsules (ANDA No. 216768) |
Case Overview
The Parties
⚖️ Plaintiffs
Acerta Pharma B.V., AstraZeneca AB, AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, and Merck Sharp & Dohme B.V., representing a consolidated innovator group protecting acalabrutinib.
🛡️ Defendants
Natco Pharma Limited (India-based) and its U.S. affiliate Natco Pharma, Inc., experienced generic pharmaceutical manufacturers challenging branded oncology products.
Patents at Issue
This landmark pharmaceutical case involved seven U.S. patents asserted by AstraZeneca and its co-plaintiffs. These patents cover the commercially significant BTK inhibitor acalabrutinib (CALQUENCE®), approved for blood cancers.
- • US9,290,504 — Core acalabrutinib compound claims
- • US9,758,524 — BTK inhibitor chemical synthesis
- • US9,796,721 — Related chemical compound claims
- • US10,167,291 — Acalabrutinib compound and method claims
- • US10,239,883 — Formulation and composition claims
- • US10,272,083 — Additional BTK inhibitor claims
- • US7,459,554 — Foundational BTK inhibitor chemistry
Developing a similar drug?
Check if your BTK inhibitor pipeline might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The parties entered a **consent judgment and permanent injunction** on April 16, 2024. This resolution permanently enjoins Natco Pharma from infringing six of the seven asserted patents by marketing generic acalabrutinib under ANDA No. 216768, except as specifically authorized by a confidential Settlement Agreement.
Key Legal Issues
This action arose as a classic **Paragraph IV ANDA certification** challenge under the Hatch-Waxman Act. Natco certified that the listed CALQUENCE® patents were either invalid, unenforceable, or not infringed. AstraZeneca and its co-plaintiffs responded with this infringement action, triggering a statutory 30-month stay of FDA approval. The settlement, formalized through a consent judgment, is significant as it provides AstraZeneca with enforceable injunctive protection while avoiding the delays and uncertainty of a full trial.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical and BTK inhibitor development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all 7 asserted patents in this BTK inhibitor space
- See which companies are most active in oncology IP
- Understand claim construction patterns for small molecules
🔍 Check My Drug’s Risk
Run a comprehensive FTO analysis for your own BTK inhibitor or oncology pipeline.
- Input your drug compound or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for your ANDA
High Risk Area
BTK Inhibitors & Acalabrutinib chemistry
7 Asserted Patents
Covering compound, synthesis, formulation
Portfolio Depth
Multi-layered IP protection
✅ Key Takeaways
Consent judgments with retained court jurisdiction provide superior enforcement tools compared to contractual-only ANDA settlements.
Search related case law →Multi-patent assertions across compound, synthesis, and formulation claims create compounded invalidity burdens — a proven deterrent strategy.
Explore precedents →Frequently Asked Questions
Seven U.S. patents were asserted: US9,290,504; US9,758,524; US9,796,721; US10,167,291; US10,239,883; US10,272,083; and US7,459,554 — covering acalabrutinib compound, synthesis, and formulation claims.
The parties reached a negotiated settlement formalized as a consent judgment on April 16, 2024, permanently enjoining Natco from marketing generic acalabrutinib under ANDA No. 216768 except as authorized by the confidential Settlement Agreement.
It reinforces that multi-patent portfolio assertions across compound and formulation claims in Hatch-Waxman litigation significantly increase innovator leverage, often driving consent judgment settlements that preserve branded exclusivity windows.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER.gov — Case No. 1:22-cv-00155 (D. Del.)
- USPTO Patent Full-Text and Image Database
- U.S. Food & Drug Administration — ANDA Process
- Cornell Legal Information Institute — Hatch-Waxman Act
- PatSnap — IP Intelligence Solutions for Pharma
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.